HomeComparePRCWF vs BTI

PRCWF vs BTI: Dividend Comparison 2026

PRCWF yields 2000000.00% · BTI yields 5.38%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PRCWF wins by $4.879226400974806e+39M in total portfolio value
10 years
PRCWF
PRCWF
● Live price
2000000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.879226400974806e+39M
Annual income
$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00
Full PRCWF calculator →
BTI
BTI
● Live price
5.38%
Share price
$58.47
Annual div
$3.15
5Y div CAGR
11.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$37.7K
Annual income
$2,786.64
Full BTI calculator →

Portfolio growth — PRCWF vs BTI

📍 PRCWF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPRCWFBTI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PRCWF + BTI cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PRCWF pays
BTI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PRCWF
Annual income on $10K today (after 15% tax)
$170,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$4,146,934,558,431,324,500,000,000,000,000,000,000,000,000,000.00/yr
BTI
Annual income on $10K today (after 15% tax)
$457.40/yr
After 10yr DRIP, annual income (after tax)
$2,368.64/yr
At 15% tax rate, PRCWF beats the other by $4,146,934,558,431,324,500,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PRCWF + BTI for your $10,000?

PRCWF: 50%BTI: 50%
100% BTI50/50100% PRCWF
Portfolio after 10yr
$2.439613200487403e+39M
Annual income
$2,439,373,269,665,485,000,000,000,000,000,000,000,000,000,000.00/yr
Blended yield
99.99%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on BTI right now

PRCWF
No analyst data
BTI
Analyst Ratings
12
Buy
4
Hold
2
Sell
Consensus: Buy
Price Target
$40.00
-31.6% upside vs current
Range: $40.00 — $40.00
Altman Z
2.1
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PRCWF buys
0
BTI buys
0
No recent congressional trades found for PRCWF or BTI in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPRCWFBTI
Forward yield2000000.00%5.38%
Annual dividend / share$2.00$3.15
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%11.3%
Portfolio after 10y$4.879226400974806e+39M$37.7K
Annual income after 10y$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00$2,786.64
Total dividends collected$4.879195005460081e+39M$14.3K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: PRCWF vs BTI ($10,000, DRIP)

YearPRCWF PortfolioPRCWF Income/yrBTI PortfolioBTI Income/yrGap
1← crossover$200,010,700$200,000,000.00$11,299$598.92+$200.00MPRCWF
2$3,738,731,768,458$3,738,517,757,009.35$12,794$703.91+$3738731.76MPRCWF
3$65,315,062,866,930,490$65,311,062,423,938,240.00$14,518$829.07+$65315062866.92MPRCWF
4$1,066,400,830,062,625,000,000$1,066,330,942,945,357,500,000.00$16,513$978.64+$1066400830062625.00MPRCWF
5$16,272,182,796,453,826,000,000,000$16,271,041,747,565,660,000,000,000.00$18,827$1,157.84+$16272182796453826560.00MPRCWF
6$232,054,240,113,661,900,000,000,000,000$232,036,828,878,069,680,000,000,000,000.00$21,518$1,373.12+$2.3205424011366188e+23MPRCWF
7$3,092,799,066,104,688,500,000,000,000,000,000$3,092,550,768,067,767,400,000,000,000,000,000.00$24,657$1,632.46+$3.0927990661046884e+27MPRCWF
8$38,524,105,697,352,694,000,000,000,000,000,000,000$38,520,796,402,351,967,000,000,000,000,000,000,000.00$28,329$1,945.74+$3.8524105697352695e+31MPRCWF
9$448,468,826,014,798,700,000,000,000,000,000,000,000,000$448,427,605,221,702,600,000,000,000,000,000,000,000,000.00$32,637$2,325.33+$4.484688260147987e+35MPRCWF
10$4,879,226,400,974,806,000,000,000,000,000,000,000,000,000,000$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00$37,708$2,786.64+$4.879226400974806e+39MPRCWF

PRCWF vs BTI: Complete Analysis 2026

PRCWFStock

Sofgen Pharma S.A., together with its subsidiaries, develops, produces, and markets pharmaceutical solutions in South America, Central America, North America, and Europe. It operates in five segments: NextGel, Procaps Colombia, Central America North (CAN), Central America South and North Andes (CASAND), and Diabetrics. The company formulates, manufactures, and markets branded prescription drugs in various therapeutic areas, including feminine care products, pain relief, skin care, digestive health, growth and development, cardiology, vision care, central nervous system, and respiratory. It also provides drugs for hospital use, such as blood clot, immunosuppressant, oncology, and analgesics products, as well as personal protective equipment, syringes, double chamber syringes, injection vials and ampoules, sterilized powder products, sterile droppers, and lyophilized solid vials. In addition, the company offers over-the-counter (OTC) consumer healthcare products through a portfolio on approximately eight therapeutic areas, including gastrointestinal, skin care, cough and cold, analgesics, and urological, as well as vitamins, minerals, and supplements in the categories of antibiotics, anti-infective, anti-parasitic, cardiovascular, feminine care, cutaneous antimycotic, pain killers, gastrointestinal, hormonals, metabolic, endocrine, nervous system, ophthalmic, osteoarticular, respiratory, diet supplements, and vitamins and minerals. Further, it provides diabetes solutions and chronic disease management tools comprising blood glucose meters, telemonitoring, oral anti-diabetics products, cosmeceuticals, insulin delivery systems, and other diabetes solutions; and contract development and manufacturing services for soft gelatin capsule-related and gummy technologies under the Softigel, Sofgen, Softcaps, and Funtrition brands. Sofgen Pharma S.A. was formerly known as Procaps Group S.A. The company was founded in 1977 and is based in Luxembourg, Luxembourg.

Full PRCWF Calculator →

BTIConsumer Staples

British American Tobacco p.l.c. provides tobacco and nicotine products to consumers in the Americas, Europe, the Asia-Pacific, the Middle East, Africa, and the United States. It offers vapour, heated, and modern oral nicotine products; combustible cigarettes; and traditional oral products, such as snus and moist snuff. The company provides its products under the Vuse, glo, Velo, Grizzly, Kodiak, Dunhill, Kent, Lucky Strike, Pall Mall, Rothmans, Newport, Natural American Spirit, and Camel brands. The company distributes its products to retail outlets. British American Tobacco p.l.c. was founded in 1902 and is based in London, the United Kingdom.

Full BTI Calculator →
📬

Get this PRCWF vs BTI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PRCWF vs SCHDPRCWF vs JEPIPRCWF vs OPRCWF vs KOPRCWF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.